1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street

Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Medical Device and Diagnostic Industry (MD+DI)

Dexcom Faces G6 Recall

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

Should You Buy DexCom Stock Before Oct. 31?

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...
MedTech Dive

Dexcom recalls G6 CGM app over software problem

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the ...

DexCom (DXCM): Assessing Valuation After Surge in Lawsuits Over Device Safety and Reliability

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
MobiHealthNews

Dexcom talks $11.3M TypeZero acquisition, new FDA clearances on Q3 earnings call

On its third quarter earnings call last week, Dexcom recapped a busy Q3 — of note, one that included the acquisition of TypeZero Technologies for $11.3 million in August as well as two new FDA ...
Fierce Biotech

Dexcom hit by FDA Class I recall for its continuous glucose monitoring system app

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...